Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Other Working Capital Changes (2018 - 2025)

UroGen Pharma (URGN) has disclosed Other Working Capital Changes for 8 consecutive years, with $1.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Working Capital Changes rose 127.74% year-over-year to $1.3 million, compared with a TTM value of -$639000.0 through Dec 2025, up 38.2%, and an annual FY2025 reading of -$639000.0, up 38.2% over the prior year.
  • Other Working Capital Changes was $1.3 million for Q4 2025 at UroGen Pharma, up from -$628000.0 in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $4.1 million in Q1 2025 and bottomed at -$5.8 million in Q4 2023.
  • Average Other Working Capital Changes over 5 years is -$239700.0, with a median of -$265500.0 recorded in 2021.
  • The sharpest move saw Other Working Capital Changes crashed 2040.15% in 2023, then surged 1870.48% in 2025.
  • Year by year, Other Working Capital Changes stood at -$262000.0 in 2021, then fell by 2.67% to -$269000.0 in 2022, then plummeted by 2040.15% to -$5.8 million in 2023, then increased by 16.52% to -$4.8 million in 2024, then surged by 127.74% to $1.3 million in 2025.
  • Business Quant data shows Other Working Capital Changes for URGN at $1.3 million in Q4 2025, -$628000.0 in Q3 2025, and -$5.5 million in Q2 2025.